The first clinical trial to target the therapeutic potential of targeting eIF4E used ribavirin monotherapy in relapsed/refractory AML, where 6/15 patients achieved objective clinical responses, including complete and partial remissions and blast responses (defined as a reduction in leukaemia cells by 50%) [18]. The gene discussed is EIF4E; the disease is acute myeloid leukemia.